A leading pharmaceutical company renowned for its innovative healthcare solutions and global reach has reported robust financial growth, with profits growing by 113 percent. In this article we will delve into its record-breaking performance, including a generous dividend of 600 percent on face value and explore strategic drivers behind this exceptional fiscal achievement.
Lupin Limited‘s stock, with a market capitalisation of Rs. 95,158 crores, rose to Rs. 2,118.90, up 2.3 percent from its previous closing price of Rs. 2,071.40. Furthermore, the stock over the past year has given a return of 27 percent.
Dividend Policy
A dividend of Rs. 12 per share has been recommended for the financial year ending March 31, 2025. This is 600 percent of the share’s face value of Rs. 2. It will be paid within 30 days after shareholders approve it at the Annual General Meeting (AGM).
Financial Highlights
In Q4FY25, the company reported revenue of Rs. 5,667 crore, marking a 14.2 percent YoY growth from Rs. 4,961 crore in Q4FY24 but a 1.7 percent QoQ decline from Rs. 5,768 crore in Q3FY25. Net profit stood at Rs. 782 crore, more than doubling YoY from Rs. 368 crore (up 112.5 percent), though down 9 percent sequentially from Rs. 859 crore in Q3FY25.
In Q4 FY25, manufacturing and other expenses were Rs. 1,687.6 crore, making up 30.3 percent of sales, up from Rs. 1,490.1 crore in Q4 FY24. The company invested Rs. 534.6 crore in R&D, which was 9.6 percent of sales. As of March 31, 2025, the company reported a net debt of Rs. -309.6 crore and a net debt-to-equity ratio of -0.02, indicating a strong cash surplus position.
Sales Mix
In FY25, the company reported consolidated sales of Rs. 22,192 crore, up 12.9 percent from FY24. North America remained the top contributor with Rs. 8,395 crore (38 percent of sales). followed by India at Rs. 7,577 crore (34 percent). Other developed markets and emerging markets contributed Rs. 2,507 crore and Rs. 2,535 crore, respectively. API sales saw modest growth of 3.1 percent to Rs. 1,177 crore. Overall product sales rose 14.1 percent year-on-year. Notably, there was no income from NCE licensing in FY25 compared to Rs. 205 crore in FY24.
Written By Fazal Ul Vahab C H
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
